S3. Rituximab for ANCA-associated vasculitides: the French experience

Presse Med. 2013 Apr;42(4 Pt 2):534-6. doi: 10.1016/j.lpm.2013.01.050. Epub 2013 Feb 26.

Authors

Pierre Charles¹, Loïc Guillevin

Affiliation

¹ AP-HP, hôpital Cochin, université Paris-Descartes, Sorbonne Paris Cité, service de médecine interne, Inserm 1016, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.

PMID: 23453207
DOI: 10.1016/j.lpm.2013.01.050

No abstract available

Publication types

Comparative Study
Review

MeSH terms

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy*
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology
Antibodies, Antineutrophil Cytoplasmic / blood
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Murine-Derived / adverse effects
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Cyclophosphamide / adverse effects
Cyclophosphamide / therapeutic use
Dose-Response Relationship, Drug
Drug Administration Schedule
France
Granulomatosis with Polyangiitis / drug therapy
Granulomatosis with Polyangiitis / immunology
Humans
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use*
Immunosuppressive Agents / therapeutic use
Infliximab
Prospective Studies
Randomized Controlled Trials as Topic
Retrospective Studies
Rituximab
Treatment Outcome

Substances

Antibodies, Antineutrophil Cytoplasmic
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Immunosuppressive Agents
Rituximab
Cyclophosphamide
Infliximab